Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for $1 billion upfront, as well as up to $400 million in certain success-based milestone payments.
The Brentford, West London-based pharmaceutical company said the acquisition will help boost its respiratory pipeline, as it will gain access to Aiolos’ anti-thymic stromal lymphopoietin monoclonal antibody, AIO-001.
According to GSK, AIO-001 is currently ready to enter phase 2 clinical development for the treatment of adult patients with asthma, with the potential for additional indications including chronic rhinosinusitis with nasal polyps.
GSK Chief Scientific Director Tony Wood said: ‘Adding AIO-001, a potentially best-in-class medicine targeting the TSLP pathway, could expand the reach of our current respiratory biologics portfolio, including to the 40% of severe asthma patients with low T2 inflammation where treatment options are still needed.’
Shares in GSK rose 0.1% to 1,550.40 pence each in London on Tuesday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.